AR076509A1 - Sal de abt-263 y formas en estado solido de la misma - Google Patents
Sal de abt-263 y formas en estado solido de la mismaInfo
- Publication number
- AR076509A1 AR076509A1 ARP100101467A ARP100101467A AR076509A1 AR 076509 A1 AR076509 A1 AR 076509A1 AR P100101467 A ARP100101467 A AR P100101467A AR P100101467 A ARP100101467 A AR P100101467A AR 076509 A1 AR076509 A1 AR 076509A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- crystalline
- abt
- powder
- compound
- Prior art date
Links
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical class C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 title abstract 3
- 239000007787 solid Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 abstract 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 abstract 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 abstract 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 abstract 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 abstract 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 abstract 3
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N 3-Methylbutan-2-one Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 abstract 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 abstract 2
- 229950004847 navitoclax Drugs 0.000 abstract 2
- 239000003960 organic solvent Substances 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- -1 (trifluoromethyl) sulfonyl Chemical group 0.000 abstract 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 abstract 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 abstract 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 abstract 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 abstract 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 abstract 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 abstract 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 abstract 1
- 229940011051 isopropyl acetate Drugs 0.000 abstract 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La ABT-263 bis-HCI y sus formas polimorficas cristalinas son ingredientes farmacéuticos activos apropiados para composiciones farmacéuticas utiles en el tratamiento de una enfermedad caracterizada por la sobreexpresion de una o más proteínas antiapoptoticas de la familia Bc1-2, por ejemplo, el cáncer. Se proveen además, procedimientos de preparacion de los mismos. Reivindicacion 1: Un compuesto caracterizado porque es bis-clorhidrato de N-(4-(4-((2-(4-clorofeniI)-5,5-dimetiI-1-ciclohex-1-en-1-iI)metil)piperazin-1-iI)benzoil)-4-(((1R)-3-(morfolin-4-il)-1-((fenilsulfanil)metil)propil)amino-3-((trifluorometil)sulfonil)bencenosulfonamida (ABT-263 bis-HCI). Reivindicacion 4: El compuesto de la reivindicacion 1 en su forma cristalina polimorfica 1, caracterizado porque al menos presenta picos en una o más cualesquiera de las siguientes posiciones en la difraccion de rayos X en polvo: 6,8, 7,2, 8,5, 18,5 y 18,7 °2theta +- 0,2s2theta. Reivindicacion 6: La forma polimorfica cristalina de la reivindicacion 4, caracterizada porque presenta un patron de difraccion de rayos X en polvo sustancialmente como el que se detalla en la siguiente tabla: Posicion del pico (°2theta)/ Intensidad relativa 6,8/59,0; 7,2/75,9; 8,5/14,3; 9,3/4,3; 11,2/6,5; 13,8/15,8; 14,0/17,7; 14,9/9,5; 16,7/17,5; 17,5/15,7; 18,2/52,2; 18,5/100,0; 18,7/95,4. Reivindicacion 7: El compuesto de la reivindicacion 1 en su forma cristalina polimorfica II, caracterizado porque al menos presenta un pico en la difraccion de rayos X en polvo en 3,7 o 7,4 s2theta +- 0,2 s2theta. Reivindicacion 9: La forma polimorfica cristalina de la reivindicacion 7, caracterizada porque presenta un patron de difraccion de rayos X en polvo sustancialmente como el que se detalla en la siguiente tabla: posicion del pico (s2theta)/ intensidad relativa: 3,7/6.0; 7,4/100,0; 12,1/5,3; 15,6/8,6; 16,1/16,2; 16,6/21,6; 18,3/70,2; 19,0/13,4. Reivindicacion 10: El compuesto de la reivindicacion 1, caracterizado porque toma la forma de un solvato cristalino que comprende ABT-263 bis-HCI solvatado con un solvente orgánico. Reivindicacion 11: El solvato de la reivindicacion 10, caracterizado porque el solvente orgánico se selecciona del grupo que consiste en etanol, 1-propanol, 2-propanol, 2-butanol, t-butanol, nitrometano, acetonitrilo, propionitrilo, formato de etilo, acetato de metilo, acetato de etilo, acetato de isopropilo, acetona, metil etil cetona, metil isopropil cetona, 1,4-dioxano, benceno, tolueno y éter butílico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17427409P | 2009-04-30 | 2009-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076509A1 true AR076509A1 (es) | 2011-06-15 |
Family
ID=42288743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101467A AR076509A1 (es) | 2009-04-30 | 2010-04-30 | Sal de abt-263 y formas en estado solido de la misma |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8362013B2 (es) |
| EP (1) | EP2424849A1 (es) |
| JP (1) | JP2012525433A (es) |
| KR (1) | KR20120005538A (es) |
| CN (1) | CN102414186A (es) |
| AR (1) | AR076509A1 (es) |
| AU (1) | AU2010242923A1 (es) |
| BR (1) | BRPI1014369A2 (es) |
| CA (1) | CA2758740A1 (es) |
| IL (1) | IL215472A0 (es) |
| MX (1) | MX2011011511A (es) |
| RU (1) | RU2011148521A (es) |
| SG (1) | SG175146A1 (es) |
| TW (1) | TW201041882A (es) |
| UY (1) | UY32598A (es) |
| WO (1) | WO2010127190A1 (es) |
| ZA (1) | ZA201107592B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100280031A1 (en) * | 2009-04-30 | 2010-11-04 | Paul David | Lipid formulation of apoptosis promoter |
| US8362013B2 (en) | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
| US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| TWI471321B (zh) * | 2009-06-08 | 2015-02-01 | 亞培公司 | Ｂｃｌ－２族群抑制劑之口服醫藥劑型 |
| TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| MX2012003408A (es) * | 2009-09-20 | 2012-08-03 | Abbott Lab | Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2. |
| CA2780177A1 (en) * | 2009-12-22 | 2011-06-30 | Abbott Laboratories | Abt-263 capsule |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| CN102584744B (zh) * | 2011-01-06 | 2015-07-01 | 上海药明康德新药开发有限公司 | 4-(4-((2-(4-氯苯基)-5,5-二甲基环己基-1-烯)甲基)哌嗪-1-基)苯甲酸的合成方法 |
| MX2016001304A (es) | 2013-07-30 | 2016-04-07 | Gilead Connecticut Inc | Polimorfo de inhibidores de syk. |
| TWI735853B (zh) | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
| CA2939121C (en) * | 2014-01-28 | 2020-11-24 | Mayo Foundation For Medical Education And Research | Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease |
| WO2015157120A1 (en) * | 2014-04-06 | 2015-10-15 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
| MX2017000610A (es) | 2014-07-14 | 2017-04-27 | Gilead Sciences Inc | Metodos combinados para tratar canceres. |
| TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| US20180133212A1 (en) | 2016-11-03 | 2018-05-17 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
| CN115028640A (zh) | 2017-08-25 | 2022-09-09 | 吉利德科学公司 | Syk抑制剂的多晶型物 |
| KR20210131372A (ko) | 2019-02-22 | 2021-11-02 | 크로노스 바이오, 인코포레이티드 | Syk 억제제로서의 축합된 피라진의 고체 형태 |
| JP2022553820A (ja) | 2019-11-05 | 2022-12-26 | アッヴィ・インコーポレイテッド | 骨髄線維症及びｍｐｎ関連障害をナビトクラクスで処置する際に使用するための投与レジメン |
| US20230165806A1 (en) * | 2021-11-19 | 2023-06-01 | Board Of Regents, The University Of Texas System | Topical Therapy of Skin Fibrosis and Melanoma |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US630663A (en) * | 1899-05-01 | 1899-08-08 | Wallace George Cook | Combined hay and stock rack. |
| US5665379A (en) | 1990-09-28 | 1997-09-09 | Pharmacia & Upjohn Aktiebolag | Lipid particle forming matrix, preparation and use thereof |
| US5536729A (en) | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
| IL111004A (en) | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
| US5759548A (en) | 1993-11-30 | 1998-06-02 | Lxr Biotechnology Inc. | Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof |
| GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| US5538737A (en) | 1994-11-30 | 1996-07-23 | Applied Analytical Industries, Inc. | Oral compositions of H2 -antagonists |
| US6964946B1 (en) | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| BE1011899A6 (fr) | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| DK1888550T3 (da) | 2005-05-12 | 2014-09-29 | Abbvie Bahamas Ltd | Apoptosepromotorer |
| JP2009513642A (ja) * | 2005-10-25 | 2009-04-02 | アボット・ラボラトリーズ | 低水溶解度の薬剤を含む製剤およびそれの使用方法 |
| CN101939008A (zh) | 2007-12-06 | 2011-01-05 | 雅培制药有限公司 | 用于治疗癌症的abt-263经口组合物 |
| CN101220008B (zh) | 2008-01-21 | 2011-04-27 | 中国科学院广州生物医药与健康研究院 | 化合物abt-263的合成方法 |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| US20100278921A1 (en) | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| US8362013B2 (en) | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
| US20100297194A1 (en) | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
| US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| EP2442789A1 (en) | 2009-06-18 | 2012-04-25 | Abbott Laboratories | Stable nanoparticulate drug suspension |
| MX2012003408A (es) | 2009-09-20 | 2012-08-03 | Abbott Lab | Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2. |
| CN101798292A (zh) | 2010-03-29 | 2010-08-11 | 无锡好芳德药业有限公司 | ABT-263衍生的新型Bcl-2蛋白抑制剂的制备 |
-
2010
- 2010-04-29 US US12/770,345 patent/US8362013B2/en not_active Expired - Fee Related
- 2010-04-30 KR KR1020117028610A patent/KR20120005538A/ko not_active Withdrawn
- 2010-04-30 SG SG2011073632A patent/SG175146A1/en unknown
- 2010-04-30 UY UY0001032598A patent/UY32598A/es not_active Application Discontinuation
- 2010-04-30 MX MX2011011511A patent/MX2011011511A/es not_active Application Discontinuation
- 2010-04-30 AR ARP100101467A patent/AR076509A1/es not_active Application Discontinuation
- 2010-04-30 JP JP2012508757A patent/JP2012525433A/ja not_active Withdrawn
- 2010-04-30 CN CN2010800185934A patent/CN102414186A/zh active Pending
- 2010-04-30 EP EP10717392A patent/EP2424849A1/en not_active Withdrawn
- 2010-04-30 AU AU2010242923A patent/AU2010242923A1/en not_active Abandoned
- 2010-04-30 WO PCT/US2010/033072 patent/WO2010127190A1/en not_active Ceased
- 2010-04-30 TW TW099113921A patent/TW201041882A/zh unknown
- 2010-04-30 BR BRPI1014369A patent/BRPI1014369A2/pt not_active IP Right Cessation
- 2010-04-30 RU RU2011148521/04A patent/RU2011148521A/ru unknown
- 2010-04-30 CA CA2758740A patent/CA2758740A1/en not_active Abandoned
-
2011
- 2011-10-02 IL IL215472A patent/IL215472A0/en unknown
- 2011-10-17 ZA ZA2011/07592A patent/ZA201107592B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20100305125A1 (en) | 2010-12-02 |
| EP2424849A1 (en) | 2012-03-07 |
| MX2011011511A (es) | 2011-11-18 |
| IL215472A0 (en) | 2011-12-29 |
| KR20120005538A (ko) | 2012-01-16 |
| RU2011148521A (ru) | 2013-06-10 |
| WO2010127190A1 (en) | 2010-11-04 |
| CA2758740A1 (en) | 2010-11-04 |
| US8362013B2 (en) | 2013-01-29 |
| BRPI1014369A2 (pt) | 2016-04-05 |
| SG175146A1 (en) | 2011-11-28 |
| AU2010242923A1 (en) | 2011-11-17 |
| UY32598A (es) | 2010-12-31 |
| TW201041882A (en) | 2010-12-01 |
| CN102414186A (zh) | 2012-04-11 |
| ZA201107592B (en) | 2012-06-27 |
| JP2012525433A (ja) | 2012-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076509A1 (es) | Sal de abt-263 y formas en estado solido de la misma | |
| MX2021009763A (es) | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. | |
| EA202192029A1 (ru) | Замещенные производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения | |
| PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
| WO2015058163A3 (en) | Heteromaromatic compounds useful for the treatment of prolferative diseases | |
| WO2018136202A3 (en) | Compounds and methods for cdk8 modulation and indications therefor | |
| PE20170189A1 (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 | |
| CY1113395T1 (el) | Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη | |
| EP4295852A3 (en) | Piperidine derivatives as inhibitors of cyclin dependent kinase 7 (cdk7) | |
| PE20131143A1 (es) | Nuevas aminopirazoloquinazolinas | |
| UY26872A1 (es) | Derivados de la 4- fenil piridina | |
| CY1112886T1 (el) | Ανοσοκατασταλτικος παραγοντας ο οποιος περιλαμβανει μια ετεροκυκλικη ενωση ως δραστικο συστατικο | |
| CU23550B7 (es) | Derivados de pirrolo-pirazol sustituidos como inhibidores de quinasa | |
| UY27617A1 (es) | 2 - (piridin -2 - ilamino) - pirido (2,3-d ) pirimidin -7 onas | |
| AR084639A1 (es) | Formas polimorficas de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico y usos del mismo | |
| CR9221A (es) | Procesos para preparar eteres aromaticos | |
| MX392270B (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| ATE455103T1 (de) | Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate | |
| EP2205088A4 (en) | NAPHTHALIN-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | |
| AR068528A1 (es) | Formas solidas de n-(5-tert-butil-isoxazol-3-il)-n'-(4(7-(2-morfolin-4-il-etoxi) imidazol(2,1-b)(1,3)benzotiazol-2-il)fenil)urea, composiciones con las mismas y usos de los mismos | |
| AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
| BRPI0510231A (pt) | composto, polimorfo cristalino, cossolvato em metanol e água, cossolvato em metanol-água, cossolvato em etanol-água, composição farmacêutica, método para administrar um agente ativo, método para preparar a forma i do snac, método para preparar a forma ii de snac, método para preparar a forma iii de snac, método para preparar a forma iv de snac, método para preparar a forma v de snac, método para preparar a forma vi de snac, composição farmacêutica e método para preparar snac amorfo | |
| PE20191236A1 (es) | Compuestos de pirazolopirimidina y metodos de uso de los mismos | |
| CO2021016433A2 (es) | Derivados heterocíclicos condensados | |
| CL2020002550A1 (es) | Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |